Filter posts

BIO Welcomes Seven New Board Members

BIO elected seven new members to its Board of Directors, voted upon at this year’s …

State Bioscience Groups Discuss Best Practices

This week the Council of State Bioscience Associations (CSBA) held its annual retreat in Scottsdale, …

Patent Reform in the News

The New York Post and The Washington Post have both run Op-eds in the last week addressing …

BIO Investor Forum Closes with Record Attendance

The 14th Annual BIO Investor Forum wrapped up in San Francisco yesterday, having exceeded all …

Fireside Chat: “Everything we knew in science 10 years ago is wrong.”

The speed of scientific innovation these days is comparable to the PC innovation era of …

Fireside Chat: James Noble Says Go for IPO

“Go for it,” was the parting advice James Noble, CEO and co-founder of Adaptimmune, had …

Politicking Biopharma Delays Cures

Forbes’ Matthew Herper ran a guest post from Robert Nelsen, cofounder and managing director of …

PTAB Ruling Proves Medical Innovation Under Attack

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …